Close Menu

NEW YORK – Drug-discovery company ReviveMed said yesterday it is collaborating with Bristol Myers Squibb to study metabolomics for cancer immunotherapy development.

Specifically, the partners will leverage Cambridge, Massachusetts-based ReviveMed's AI-driven platform to better understand mechanisms of immunotherapy response and resistance in cancer patients.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Sponsored by

Diverse components of the UC Davis campus have been mobilized to deploy HTP testing to provide a safe working environment and keep the pandemic under control.